TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03377296

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plasmodium vivax infection
Description: Two healthy human volunteers are exposed to the bites of five infectious mosquitoes per participant (by placing their forearms over the pot containing mosquitoes) for 5-10 minutes. Fed mosquitoes (as indicated by the presence of a blood meal in the abdomen) are individually dissected and assessed for sporozoite load (graded 0 to +4; a gland rating of +2 or more, representing 10 or more observed sporozoites, qualifies as being infectious). If, by this method the volunteer is found to have been inoculated by less than five infected mosquitoes, further mosquitoes are allowed to feed on the volunteer until a total of 5 appropriately infected mosquitoes have fed. The bite-challenge procedure continues until the subject has been bitten by 5 infectious mosquitoes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Collection of 250mL blood from each volunteer (N=2)
Description: Collection of 250mL of P. vivax-infected blood from each volunteer when a threshold parasitaemia/ symptoms are met
Study: NCT04017338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glecaprevir 300 MG / Pibrentasvir 120 MG Oral Tablet
Description: A potent and effective antiviral medication that has recently been approved for use in Canada with over 99% cure rates.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10Mg Oral Tablet
Description: A cholesterol-lowering medication that also blocks entry of HCV into liver cells.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ex Vivo Lung Perfusion
Description: A technology that allows for the assessment and treatment of lungs prior to transplant.
Study: NCT03132675

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tavokinogene telseplasmid
Description: Intratumoral tavokinogene telseplasmid (tavo, pIL-12) delivered by electroporation every 6 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous 3 weekly treatments

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ImmunoPulse
Description: Device that electroporates the tavokinogene telseplasmid
Study: NCT02070770

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Very low calorie diet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard weight loss diet
Study: NCT02770729

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Intracameral injection of moxifloxacin at conclusion of cataract surgery

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: No injection of moxifloxacin
Description: No intracameral injection of moxifloxacin at conclusion of cataract surgery
Study: NCT00401258

Intervention type: DRUG
Group type: OTHER
Intervention: duloxetine
Description: 30mg oral duloxetine per day for one week, titrated up to 60mg per day at day 8, concluded by a one week taper period of 4 days of 30mg pills at the conclusion of the study, followed by 3 days on no medication (4+3 days=1 week), concluded with a post-taper follow-up appointment with a study physician.
Study: NCT01465763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tofacitinib
Description: 10 mg oral BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Plabebo oral BID
Study: NCT00600470

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Doctor-office collaborative care (DOCC) management
Description: DOCC is an evidence-based psychosocial treatment approach that incorporates (1) adaptation of an evidence-based collaborative care approach using the chronic care model and participatory management theory to enhance training, implementation, and sustainability; (2) revised protocol content that includes medication management for ADHD, brief anxiety management, and attention to parental/partner dysfunction; (3) technological developments to facilitate screening/assessment, monitoring, and communication; and (4) an improved methodology that includes new samples, measures, and settings.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual (TAU)
Description: TAU involves routine care: psychoeducation and referral to outside providers.
Study: NCT05261308

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: new prosthesis
Description: Operation to fix the new prosthesis
Study: NCT03306420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M4112
Description: All participants who received M4112 100,200,400,600 and 800 mg twice daily in 28-day cycles, starting from Day 1 of each cycle until confirmed disease progression or unacceptable toxicity (up to 15 Months).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M4112
Description: All participants who received M4112 100,200,400,600 and 800 mg twice daily in 28-day cycles, starting from Day 1 of each cycle until confirmed disease progression or unacceptable toxicity (up to 15 Months).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M4112
Description: All participants who received M4112 100,200,400,600 and 800 mg twice daily in 28-day cycles, starting from Day 1 of each cycle until confirmed disease progression or unacceptable toxicity (up to 15 Months).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M4112
Description: All participants who received M4112 100,200,400,600 and 800 mg twice daily in 28-day cycles, starting from Day 1 of each cycle until confirmed disease progression or unacceptable toxicity (up to 15 Months).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M4112
Description: All participants who received M4112 100,200,400,600 and 800 mg twice daily in 28-day cycles, starting from Day 1 of each cycle until confirmed disease progression or unacceptable toxicity (up to 15 Months).
Study: NCT03346005

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aeonose
Description: An electronic nose device is an artificial olfactory system that analyses volate organic compounds (VOCs) in exhaled breath. The AeonoseTM is a handheld device of 650 gram. A nose clip will be used to prevent the entry of non-filtered air and patients will be instructed to enclose the mouthpiece with their mouth at all times. A measurement cycle lasts for about 15 minutes, of which 5 minutes of in-and exhalation by the patient takes place.
Study: NCT02204657

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Glucose Monitoring System
Description: Patients in the intervention group will receive Continuous Glucose Monitoring(CGMS) at weeks 28, 32 and 36 and have the CGMS reviewed at weeks 29, 33 and 37 and management adjusted based on the CGMS readings
Study: NCT00757627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoricoxib
Description: etoricoxib 60 mg QD for 4 weeks.
Study: NCT00858689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: 50-100 mg PO BID for 8 weeks with an option for a 1 year extension.
Study: NCT01343758

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 5% dextrose in normal saline
Description: Subjects will be randomized to receive a intravenous fluid bolus of 5% dextrose in normal saline or normal saline
Study: NCT02867917

Intervention type: DRUG
Group type: OTHER
Intervention: Volcolon sugar free
Description: 1 sachet contains 4 g powder 980mg/g psyllium fibers x 4 g per sachet = 3.92 g psyllium fibers/sachet

Intervention type: DRUG
Group type: OTHER
Intervention: Metamucil Orange
Description: 1 sachet contains 3.4 g psyllium fibers So 25 ml contains 0.425 g psyllium fibers

Intervention type: DRUG
Group type: OTHER
Intervention: Psyllium Orange
Description: 1 sachet contains 3.25 g psyllium fibers So 25 ml contains 0.406 g psyllium fibers
Study: NCT02471989

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low-FODMAP diet

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: GERD diet
Study: NCT00798291

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ad lib diet and Control placebo
Description: one packet with water two times a day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ad lib diet and An 777
Description: one packet with water two times a day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ad lib diet/ placebo/ exercise
Description: one packet with water two times a day; resistance training three times a week

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ad lib diet; AN 777; exercise
Description: one packet with water two times a day; resistance training three times a week
Study: NCT04118881

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Ear Acupuncture
Description: Auricular Acupuncture (AA) is a micro-system of acupuncture and moxibustion initiated by Chinese and French doctors. All acupoints are distributed in the ear. In the treatment of perioperative patients, ear needle is far away from the surgical wound and its minimally invasive and tolerable position has obvious advantages over body needle.AA can regulate the function of corresponding organs at acupoints. The theoretical basis of TCM is holistic concept and syndrome differentiation and treatment.AA can prevent and treat perioperative nausea and vomiting. A number of randomized controlled trials and retrospective studies have confirmed that AA has obvious advantages in preventing nausea and vomiting in perioperative period compared with routine prevention, and its possible mechanism is ear-directed stimulation of the ear branch of vagus nerve, thereby enhancing gastrointestinal motility and accelerating gastric emptying.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ear Acupuncture
Description: Auricular Acupuncture (AA) is a micro-system of acupuncture and moxibustion initiated by Chinese and French doctors. All acupoints are distributed in the ear. In the treatment of perioperative patients, ear needle is far away from the surgical wound and its minimally invasive and tolerable position has obvious advantages over body needle.AA can regulate the function of corresponding organs at acupoints. The theoretical basis of TCM is holistic concept and syndrome differentiation and treatment.AA can prevent and treat perioperative nausea and vomiting. A number of randomized controlled trials and retrospective studies have confirmed that AA has obvious advantages in preventing nausea and vomiting in perioperative period compared with routine prevention, and its possible mechanism is ear-directed stimulation of the ear branch of vagus nerve, thereby enhancing gastrointestinal motility and accelerating gastric emptying.
Study: NCT02700659

Intervention type: OTHER
Intervention: Cxbladder
Description: Cxbladder is a non invasive UC detection test measuring five messenger RNA (mRNA) biomarkers present at elevated levels in patients presenting with urothelial carcinoma.
Study: NCT03624153

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Robotic-assisted intervention
Description: Participants received the 12-session robot-assisted intervention 3 sessions a week for 4 consecutive weeks. Each session consisted of 20-minute continuous passive motion, 20-minute active motion practice, and 30-minute task-oriented practice.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation intervention
Description: Participants received the 12-session conventional rehabilitation intervention 3 sessions a week for 4 consecutive weeks. The intervention consisted of warm up including range of motion exercise, and strengthening exercise followed by task-oriented training for activities of daily living.
Study: NCT02202785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN0264
Description: MLN0264 IV infusion
Study: NCT01294436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Oral Dose 5 or 10 mg
Study: NCT01987362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6870810
Description: Participants will receive RO6870810 at different planned doses with a starting dose of 0.03 mg/kg to a maximum dose of 0.85 mg/kg SC on Days 1 to 14 in a 21-day treatment cycle or on Days 1 to 21 in a 28-day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6870810
Description: Participants will receive RO6870810 at different planned doses with a starting dose of 0.03 mg/kg to a maximum dose of 0.85 mg/kg SC on Days 1 to 14 in a 21-day treatment cycle or on Days 1 to 21 in a 28-day treatment cycle.
Study: NCT04356534

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: plasma therapy using convalescent plasma with antibody against SARS-CoV-2
Description: convalescent patient plasma plus routine local standard of care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine care for COVID-19 patients
Description: local standard of care which include antivirals and supportive care
Study: NCT04743531

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HEROs
Description: Intervention Description: The intervention will consist of a 6-week family workshop series, held one evening per week for six consecutive weeks. The intervention modules will be delivered by trained researchers at two preschool sites in rural Colorado in Fall 2019 and Spring 2020. The primary caregiver and preschool child will be the targets of the study. Each of the workshops will be structured to include joint caregiver-child activities and programming that is tailored for caregivers and children individually. Caregivers will learn about and engage in activities related to healthy eating and picky eating; physical activity and motor development; and parenting strategies. Children will participate in activities focused on healthful eating and physical activity that supports content their parents are learning.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HEROs
Description: Intervention Description: The intervention will consist of a 6-week family workshop series, held one evening per week for six consecutive weeks. The intervention modules will be delivered by trained researchers at two preschool sites in rural Colorado in Fall 2019 and Spring 2020. The primary caregiver and preschool child will be the targets of the study. Each of the workshops will be structured to include joint caregiver-child activities and programming that is tailored for caregivers and children individually. Caregivers will learn about and engage in activities related to healthy eating and picky eating; physical activity and motor development; and parenting strategies. Children will participate in activities focused on healthful eating and physical activity that supports content their parents are learning.
Study: NCT01754753

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telephone Friendship groups
Study: NCT00208325

Intervention type: DEVICE
Group type: OTHER
Intervention: P.F.C Sigma Fixed Bearing total knee system
Description: Orthopaedic implant for total knee replacement

Intervention type: DEVICE
Group type: OTHER
Intervention: P.F.C Sigma Fixed Bearing total knee system
Description: Orthopaedic implant for total knee replacement

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: P.F.C Sigma RP Mobile Bearing knee system
Description: Orthopaedic implant for total knee replacement

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: P.F.C Sigma RP Mobile Bearing knee system
Description: Orthopaedic implant for total knee replacement
Study: NCT01701336

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad6NSmut, MVA-NSmut
Description: 2 doses Ad6NSmut at week 0 and 4, then 2 doses of MVA-NSmut at weeks 8 and 12. PEG-IFN/RBV therapy starts at week 10 after first vaccination
Study: NCT01766713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: 10mg daily oral dose of ezetimibe

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ezetimibe
Description: 10mg daily oral dose of ezetimibe
Study: NCT02119247

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CHF 6001 dry powder for inhalation via NEXThaler®

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CHF 6001 DPI capsules for inhalation via Aerolizer
Study: NCT01774045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDC-1421

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00108745

Intervention type: OTHER
Group type: OTHER
Intervention: Clinical Observation
Description: Undergo observation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel Poliglumex
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT00243074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cediranib maleate
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00106301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FK228 (romidepsin)
Description: Patients were continued at the same dose of romidepsin as in the previous study, which could have been 13 mg/m2 or a reduced dose of 10 mg/m2, administered intravenously over 4 hours on Days 1, 8, and 15 of each 28-day cycle.
Study: NCT04444934

Intervention type: OTHER
Intervention: histological examination
Description: Patients were classified in two groups based on the surgeon's visual examination of the right diaphragmatic peritoneum. The accuracy of visual examination has been assessed comparing surgeon's opinions to histological examination

Intervention type: OTHER
Intervention: histological examination
Description: Patients were classified in two groups based on the surgeon's visual examination of the right diaphragmatic peritoneum. The accuracy of visual examination has been assessed comparing surgeon's opinions to histological examination
Study: NCT03525470

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Water
Description: 150 mil of water was drunk on two occasions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No drink
Description: Although body weight lost no drink consumed
Study: NCT00921947

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAX102
Description: Universal M2e influenza vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAX102
Description: Universal M2e influenza vaccine
Study: NCT01739023

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Human Schwann Cells
Description: Schwann cells harvested from the sural nerve of the participant will be autologously transplanted into the epicenter of the participant's spinal cord injury.
Study: NCT00542204

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online disease management
Description: The Personalized Health Care Program couples a multidisciplinary care management team with an EHR-integrated Online Disease Management (ODM) system.
Study: NCT00664534

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: patient glucose-level dependent, injection, as needed per patient glucose level, 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro Premix (mid-mixture and low-mixture)
Description: patient glucose level dependent, injection, as needed per patient glucose level, 48 weeks
Study: NCT00600613

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: cone beam imaging
Description: All study patients will undergo simulation, treatment planning and verification as currently practiced. The contrast injection and cone beam imaging will be added to the standard procedure just prior to treatment delivery on the first and last days of treatment only.
Study: NCT04797234

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: There will be no intervention to the control group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experiment
Description: The experimental group will be trained for 6 weeks.
Study: NCT03003585

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Direct laryngoscope
Description: This device is used in endotracheal intubation and tonopen device for measuring of intraocular pressure. The investigators want to evaluate which one is better.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fiberoptic bronchoscope
Description: This device is used in endotracheal intubation and tonopen device for measuring of intraocular pressure. The investigators want to evaluate which one is better.
Study: NCT03242343

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VasQ
Description: An external support device for AV fistula
Study: NCT04494204

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Immunofree tablets and Reginmune capsule
Description: 2 Immunofree tablets thrice a day at an interval of 4-5 hours for 10 days and 1 Reginmune capsule twice a day for 10 days

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Immunofree tablets and Reginmune capsule
Description: 2 Immunofree tablets thrice a day at an interval of 4-5 hours for 10 days and 1 Reginmune capsule twice a day for 10 days
Study: NCT00618579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LWMH in TB-402 treated subjects or TB-402 in warfarin treated subjects
Description: Administration of LMWH in healthy male subjects treated with TB-402 and administration of TB-402 in healthy male subjects treated with warfarin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LWMH in TB-402 treated subjects or TB-402 in warfarin treated subjects
Description: Administration of LMWH in healthy male subjects treated with TB-402 and administration of TB-402 in healthy male subjects treated with warfarin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LWMH in TB-402 treated subjects or TB-402 in warfarin treated subjects
Description: Administration of LMWH in healthy male subjects treated with TB-402 and administration of TB-402 in healthy male subjects treated with warfarin

Intervention type: DRUG
Group type: OTHER
Intervention: LWMH in TB-402 treated subjects or TB-402 in warfarin treated subjects
Description: Administration of LMWH in healthy male subjects treated with TB-402 and administration of TB-402 in healthy male subjects treated with warfarin